Literature DB >> 25310995

Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?

Jean Bastin1, Jean-Paul Bonnefont, Fatima Djouadi, Jean-Louis Bresson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25310995     DOI： 10.1007/s10545-014-9775-7

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  5 in total

1.  Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency.

Authors:  J P Bonnefont; J Bastin; P Laforêt; F Aubey; A Mogenet; S Romano; D Ricquier; S Gobin-Limballe; A Vassault; A Behin; B Eymard; J L Bresson; F Djouadi
Journal:  Clin Pharmacol Ther       Date:  2010-05-26       Impact factor: 6.875

2.  Bezafibrate for an inborn mitochondrial beta-oxidation defect.

Authors:  Jean-Paul Bonnefont; Jean Bastin; Anthony Behin; Fatima Djouadi
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

3.  Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.

Authors:  Mette Cathrine Ørngreen; Karen Lindhardt Madsen; Nicolai Preisler; Grete Andersen; John Vissing; Pascal Laforêt
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

4.  Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations.

Authors:  Mette C Ørngreen; Morten Dunø; Rasmus Ejstrup; Ernst Christensen; Marianne Schwartz; Massimo Sacchetti; John Vissing
Journal:  Ann Neurol       Date:  2005-01       Impact factor: 10.422

5.  Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency.

Authors:  Mette C ØRngreen; Mette G Nørgaard; Massimo Sacchetti; Baziel G M van Engelen; John Vissing
Journal:  Ann Neurol       Date:  2004-08       Impact factor: 10.422
  5 in total
  5 in total

Review 1.  Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.

Authors:  Kenji Yamada; Takeshi Taketani
Journal:  J Hum Genet       Date:  2018-11-06       Impact factor: 3.172

Review 2.  Electron transfer flavoprotein and its role in mitochondrial energy metabolism in health and disease.

Authors:  Bárbara J Henriques; Rikke Katrine Jentoft Olsen; Cláudio M Gomes; Peter Bross
Journal:  Gene       Date:  2021-01-13       Impact factor: 3.688

Review 3.  Redox signalling and mitochondrial stress responses; lessons from inborn errors of metabolism.

Authors:  Rikke K J Olsen; Nanna Cornelius; Niels Gregersen
Journal:  J Inherit Metab Dis       Date:  2015-05-30       Impact factor: 4.982

Review 4.  Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases.

Authors:  Zaza Khuchua; Aleksandr I Glukhov; Arnold W Strauss; Sabzali Javadov
Journal:  Int J Mol Sci       Date:  2018-11-04       Impact factor: 5.923

5.  Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan.

Authors:  Kenji Yamada; Hideaki Shiraishi; Eishin Oki; Mika Ishige; Toshiyuki Fukao; Yusuke Hamada; Norio Sakai; Fumihiro Ochi; Asami Watanabe; Sanae Kawakami; Kazuyo Kuzume; Kenji Watanabe; Koji Sameshima; Kiyotaka Nakamagoe; Akira Tamaoka; Naoko Asahina; Saki Yokoshiki; Takashi Miyakoshi; Kota Ono; Koji Oba; Toshiyuki Isoe; Hiroshi Hayashi; Seiji Yamaguchi; Norihiro Sato
Journal:  Mol Genet Metab Rep       Date:  2018-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.